Rothschild & Co. Asset Management US Inc. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 22.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 453,356 shares of the company’s stock after selling 131,776 shares during the quarter. Johnson & Johnson accounts for 1.2% of Rothschild & Co. Asset Management US Inc.’s portfolio, making the stock its 5th biggest holding. Rothschild & Co. Asset Management US Inc.’s holdings in Johnson & Johnson were worth $67,495,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Newfound Research LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at $28,000. Islay Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $42,000. FAI Wealth Management raised its position in Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC raised its position in Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares in the last quarter. Finally, HWG Holdings LP bought a new stake in Johnson & Johnson during the 2nd quarter valued at $49,000. Institutional investors own 67.44% of the company’s stock.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.
Johnson & Johnson stock opened at $146.36 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The business’s 50-day simple moving average is $145.51 and its two-hundred day simple moving average is $146.57. The company has a market cap of $385.30 billion, a PE ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. The business had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.12 EPS. As a group, analysts predict that Johnson & Johnson will post 7.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 annualized dividend and a yield of 2.76%. Johnson & Johnson’s payout ratio is presently 46.54%.
Several research firms have recently commented on JNJ. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday. Cantor Fitzgerald boosted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Credit Suisse Group boosted their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $164.93.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Article: What are momentum indicators and what do they show?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.